TVTX | tickerfilter.com

Fundamental analysis

45%

Profitability 35%

Dept financing 40%

Liquidity 73%

Performance 50%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-0.02%

1 Month

47.54%

3 Months

34.78%

6 Months

36.90%

1 Year

110.80%

2 Year

647.44%

Key data

Stock price

$40.81

P/E Ratio

0.00

DAY RANGE

$40.50 - $41.43

EPS

-$0.29

52 WEEK RANGE

$13.88 - $43.31

52 WEEK CHANGE

$103.24

MARKET CAP

3.419 B

YIELD

N/A

SHARES OUTSTANDING

92.242 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-05-2025

BETA

1.56

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,706,332

AVERAGE 30 VOLUME

$2,746,649

Company detail

CEO: Eric M. Dube
Region: US
Website: travere.com
Employees: 460
IPO year: 2008

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Travere Therapeutics, Inc. focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the. treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy.

TVTX - Travere Therapeutics, Inc.